CMRX Quote, Financials, Valuation and Earnings

Jazz Pharmaceuticals PLC has a net margin of -40270.18% compared to Chimerix's net margin of 17.56%. Chimerix's return on equity of -56.65% beat Jazz Pharmaceuticals PLC's return on equity of 14.39%.

Chimerix has a consensus price target of $8.54, signalling upside risk potential of 0.47%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $193.22 which suggests that it could grow by 52.87%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Chimerix, analysts believe Jazz Pharmaceuticals PLC is more attractive than Chimerix.

Chimerix has a beta of 0.324, which suggesting that the stock is 67.586% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.239%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $57K, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Chimerix's net income of -$23M is lower than Jazz Pharmaceuticals PLC's net income of $191.1M. Notably, Chimerix's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 14.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 1.99x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -40270.18% compared to Chimerix's net margin of -117.16%. Chimerix's return on equity of -56.65% beat Moderna's return on equity of -29.09%.

Chimerix has a consensus price target of $8.54, signalling upside risk potential of 0.47%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 68.81%. Given that Moderna has higher upside potential than Chimerix, analysts believe Moderna is more attractive than Chimerix.

Chimerix has a beta of 0.324, which suggesting that the stock is 67.586% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $57K, which are smaller than Moderna quarterly revenues of $956M. Chimerix's net income of -$23M is higher than Moderna's net income of -$1.1B. Notably, Chimerix's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 3.90x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Omeros has a net margin of -40270.18% compared to Chimerix's net margin of --. Chimerix's return on equity of -56.65% beat Omeros's return on equity of --.

Chimerix has a consensus price target of $8.54, signalling upside risk potential of 0.47%. On the other hand Omeros has an analysts' consensus of $36.00 which suggests that it could grow by 303.59%. Given that Omeros has higher upside potential than Chimerix, analysts believe Omeros is more attractive than Chimerix.

Chimerix has a beta of 0.324, which suggesting that the stock is 67.586% less volatile than S&P 500. In comparison Omeros has a beta of 2.035, suggesting its more volatile than the S&P 500 by 103.48%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chimerix pays -- of its earnings as a dividend. Omeros pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $57K, which are larger than Omeros quarterly revenues of --. Chimerix's net income of -$23M is higher than Omeros's net income of -$32.2M. Notably, Chimerix's price-to-earnings ratio is -- while Omeros's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus -- for Omeros. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -40270.18% compared to Chimerix's net margin of 24.22%. Chimerix's return on equity of -56.65% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Chimerix has a consensus price target of $8.54, signalling upside risk potential of 0.47%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 45.17%. Given that Regeneron Pharmaceuticals has higher upside potential than Chimerix, analysts believe Regeneron Pharmaceuticals is more attractive than Chimerix.

Chimerix has a beta of 0.324, which suggesting that the stock is 67.586% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Chimerix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.14% to investors and pays a quarterly dividend of $0.88 per share. Chimerix pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Chimerix quarterly revenues are $57K, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Chimerix's net income of -$23M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Chimerix's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 16.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chimerix is -- versus 5.15x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.